All sufferers with breast most cancers who could also be candidates for antibody-drug conjugate remedy ought to endure HER2 testing to find out eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent that was authorized by the FDA on Jan. 27, in line with Dr. Debu Tripathy, who says that the agent has proven sturdy responses and superiority over customary chemotherapy, although its efficacy in contrast with focused therapies stays unclear.
In an interview with CURE®, Tripathy mentioned the significance of understanding the distinctions between HER2-low and HER2-ultralow, in addition to highlighted how sufferers can talk about testing with their oncologists. Tripathy is at the moment a professor and chairman of the Division of Breast Medical Oncology, Division of Most cancers Drugs, The College of Texas MD Anderson Most cancers Middle, in Houston, and the editor-in-chief of CURE®.
Transcript:
The very first thing is to be sure that their tumor is being examined for HER2 content material, all people’s tumor who could also be a candidate for antibody-drug conjugate remedy needs to be examined as a result of it leaves open the opportunity of utilizing Enhertu. We all know that, basically, the info has proven that sufferers can get sturdy responses to this agent, and it’s higher than the standard-of-care chemotherapy. [However], we do not know the way it might get up towards focused therapies; that is an space that wants additional examine.
We do use sure focused therapies, like PI3K focused remedy in sufferers which have alterations in that pathway and so forth. However relating to shifting over to chemotherapy, we do know from the DESTINY-Breast sequence of trials that this actually stays a viable and powerful risk to make use of this antibody-drug conjugate. That is why it is vital that we all know that we no less than must do HER2 testing.
Secondly, it is vital that the pathologists which are doing the testing are outfitted, educated and capable of report back to you the extent of HER2-positive versus -negative. Throughout the unfavorable teams, which of them are HER2-low, that might be 1+ and a pair of+ — the two+, after all, being FISH unfavorable — these could be the HER2-low that we’re extra acquainted with, however now the HER2-ultralow class is being added. This actually does require … that the pathologist is acquainted with the ultralow idea, [consisting of] this very faint, partial membrane staining, and is one thing that they need to have the ability to report out. That is a crucial distinction, as a result of these sufferers are additionally going to be eligible for remedy with the Enhertu [agent].
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
